Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data [Seeking Alpha]
Tango Therapeutics, Inc. (TNGX)
Company Research
Source: Seeking Alpha
Summary Tango Therapeutics, Inc. offers high-risk, high-reward exposure to PRMT5-inhibitor drugs, with two candidates, TNG908 and TNG462, targeting MTAP-deleted cancers, a substantial market opportunity. TNGX stock volatility is influenced by competitors' PRMT5 data, with recent fluctuations driven by Amgen and Mirati's clinical results. Tango's financial stability is supported by $300M in cash, a Gilead partnership, and a funding runway until 2027, covering key clinical readouts. Despite the high risk, Tango's differentiated approach and potential blockbuster candidates make TNGX stock an intriguing speculative buy ahead of critical data readouts. Hispanolistic/E+ via Getty Images Investment Overview — Tango's Share Price Volatility Based On Competitor's Progress When I last covered Tango Therapeutics, Inc. NASDAQ: TNGX ) for Seeking Alpha, in January of this year, I gave the stock a “Buy” rating. I highlighted the fact that the Boston, Massachusetts-based biotech is o
Show less
Read more
Impact Snapshot
Event Time:
TNGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TNGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TNGX alerts
High impacting Tango Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TNGX
News
- Tango Therapeutics, Inc. (NASDAQ: TNGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $13.00 price target on the stock.MarketBeat
- Tango Therapeutics to Participate in Upcoming Investor ConferencesBusiness Wire
- Tango Therapeutics Second Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
- Tango Therapeutics, Inc. (NASDAQ: TNGX) had its price target raised by analysts at Wedbush from $11.00 to $13.00. They now have an "outperform" rating on the stock.MarketBeat
- Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
TNGX
Earnings
- 8/7/24 - Beat
TNGX
Sec Filings
- 9/17/24 - Form 4
- 9/13/24 - Form 144
- 9/9/24 - Form 4
- TNGX's page on the SEC website